Skip Navigation


Cardiovascular Research Advance Access originally published online on October 9, 2009
Cardiovascular Research 2009 84(3):341-342; doi:10.1093/cvr/cvp339
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
84/3/341    most recent
cvp339v2
cvp339v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Immenschuh, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Immenschuh, S.
Related Collections
Right arrowRelated Article
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.

Endocannabinoid signalling as an anti-inflammatory therapeutic target in atherosclerosis: does it work?

Stephan Immenschuh*

Institute for Transfusion Medicine, Hanover Medical School, Carl-Neuberg-Str. 1, 30625 Hanover, Germany

* Corresponding author. Tel: +49 511 532 6704/9714; fax: +49 511 532 2079. E-mail address: immenschuh.stephan@mh-hannover.de

This editorial refers to ‘CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages’ by K.H. Han et al., pp. 378–386, this issue.

The first 10% of the full text of this article appears below.

The endocannabinoid system is a physiological signalling network that has attracted major attention in recent years because of its therapeutic potential for the treatment of various pathological conditions, including cardiovascular disease. More specifically, targeted modulation of the major receptors of this system, the G-protein-coupled cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptors, has been implicated in the protection against atherosclerosis. Accumulating evidence suggests that specific blockage of these receptors may have beneficial effects on classical cardiovascular risk factors such as hypercholesterolaemia, obesity, and impaired glucose tolerance.1 In a pioneering report, it was demonstrated that low levels of the cannabinoid derivative delta-9-tetrahydrocannabinoid reduced the progression of . . . [Full Text of this Article]


   Funding
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article

CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages
Ki Hoon Han, Sunny Lim, Jewon Ryu, Cheol-Whan Lee, Yuna Kim, Ju-Hee Kang, Soon-Suk Kang, Yeong Ki Ahn, Chan-Sik Park, and Jae Joong Kim
Cardiovasc Res 2009 84: 378-386. [Abstract] [Full Text] [PDF]